CERE Annual Cash & Cash Equivalents
$416.46 M
+$279.94 M+205.06%
31 December 2023
Summary:
As of February 5, 2025, CERE annual cash & cash equivalents is $416.46 million, with the most recent change of +$279.94 million (+205.06%) on December 31, 2023. During the last 3 years, it has risen by +$32.84 million (+8.56%).CERE Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CERE Quarterly Cash And Cash Equivalents
$320.44 M
-$96.03 M-23.06%
31 March 2024
Summary:
As of February 5, 2025, CERE quarterly cash and cash equivalents is $320.44 million, with the most recent change of -$96.03 million (-23.06%) on March 31, 2024. Over the past year, it has increased by +$164.72 million (+105.78%).CERE Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CERE Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +205.1% | +105.8% |
| 3 y3 years | +8.6% | +249.2% |
| 5 y5 years | +423.5% | +249.2% |
CERE Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | ||||
| 5 y | 5-year | ||||
| alltime | all time | at high | -52.2% |
Cerevel Therapeutics Holdings Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2024 | - | $320.44 M(-23.1%) |
| Dec 2023 | $416.46 M(+205.1%) | $416.46 M(+167.4%) |
| Sept 2023 | - | $155.72 M(-11.4%) |
| June 2023 | - | $175.76 M(+14.3%) |
| Mar 2023 | - | $153.82 M(+12.7%) |
| Dec 2022 | $136.52 M | $136.52 M(-45.1%) |
| Sept 2022 | - | $248.60 M(+79.9%) |
| June 2022 | - | $138.22 M(+50.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | $91.76 M(-52.5%) |
| Dec 2021 | $193.02 M(-49.7%) | $193.02 M(-71.2%) |
| Sept 2021 | - | $669.68 M(+104.8%) |
| June 2021 | - | $327.06 M(-4.7%) |
| Mar 2021 | - | $343.29 M(-10.5%) |
| Dec 2020 | $383.62 M(+382.2%) | $383.62 M(>+9900.0%) |
| Sept 2020 | - | $609.40 K |
| Dec 2019 | $79.55 M | - |
FAQ
- What is Cerevel Therapeutics Holdings annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Cerevel Therapeutics Holdings?
- What is Cerevel Therapeutics Holdings annual cash & cash equivalents year-on-year change?
- What is Cerevel Therapeutics Holdings quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Cerevel Therapeutics Holdings?
- What is Cerevel Therapeutics Holdings quarterly cash and cash equivalents year-on-year change?
What is Cerevel Therapeutics Holdings annual cash & cash equivalents?
The current annual cash & cash equivalents of CERE is $416.46 M
What is the all time high annual cash & cash equivalents for Cerevel Therapeutics Holdings?
Cerevel Therapeutics Holdings all-time high annual cash & cash equivalents is $416.46 M
What is Cerevel Therapeutics Holdings annual cash & cash equivalents year-on-year change?
Over the past year, CERE annual cash & cash equivalents has changed by +$279.94 M (+205.06%)
What is Cerevel Therapeutics Holdings quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of CERE is $320.44 M
What is the all time high quarterly cash and cash equivalents for Cerevel Therapeutics Holdings?
Cerevel Therapeutics Holdings all-time high quarterly cash and cash equivalents is $669.68 M
What is Cerevel Therapeutics Holdings quarterly cash and cash equivalents year-on-year change?
Over the past year, CERE quarterly cash and cash equivalents has changed by +$164.72 M (+105.78%)